# US 2006/0052370 A1 · Methods and compositions for treating nociceptive pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0052370 A1
- Document ID: US20060052370A1
- Status: Published application
- Kind: A1
- Application number: 11/211,900
- Filed: 2005-08-24
- Published: 2006-03-09
- Earliest claimed: 2004-08-24
- Inventors: Laurence Meyerson; Gregory Went; Timothy Burkoth
- Web page: https://patentgrep.com/patent/US20060052370A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/415: 1,2-Diazoles
- A61K 31/465: Nicotine; Derivatives thereof
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods and compositions useful for the treatment and prevention of pain.

## Claims

### Claim 1

A pharmaceutical composition comprising:
(a) an NMDA receptor antagonist;
(b) a second agent, wherein said agent is an opiate narcotic agent, a non-steroidal anti-inflammatory agent, or an anesthetic; and
(c) a pharmaceutically acceptable carrier, provided said pharmaceutical composition does not include a 3-pyridyl ether compound.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein at least one of said NMDA receptor antagonist or said second agent is provided in an extended release dosage form.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein said NMDA receptor antagonist has a dC/dT less than about 80% of the rate for the IR formulation.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein said NMDA receptor antagonist has a Cmax/Cmean of approximately 1.6 or less approximately 2 hours to at least 12 hours after said composition is introduced into a subject.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the relative Cratio.var of said NMDA receptor antagonist and said second agent is less than 100% from 2 hour to 12 hours after said composition is introduced into a subject.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the relative Cratio.var of said NMDA receptor antagonist and said second agent is less than 70% of the corresponding IR formulation from 2 hour to 12 hours after said composition is introduced into a subject.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the NMDA receptor antagonist is selected from the group consisting of memantine, amantidine, rimantidine, ketamine, eliprodil, ifenprodil, dizocilpine, remacemide, iamotrigine, riluzole, aptiganel, phencyclidine, flupirtine, celfotel, felbamate, neramexane, spermine, spermidine, levemopamil, dextromethorphan, dextrorphan, and pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein said opiate narcotic agent is selected from the group consisting of morphine, codeine, hydromorphone, oxymorphone, hydrocodone, oxycodone, meperidine, propoxyphene, tramadol, butorphanol, buprenorphine, and fentanyl.

### Claim 9 (depends on 1)

The method of claim 1, wherein said nonsteroidal anti-inflammatory agent is selected from the group consisting of acetaminophen, ketoralac, diclofenac, ibuprofen, naproxen, indomethacin, piroxicam, celecoxib, rofecoxib, and valdecoxib, and acetylsalicylate.

### Claim 10 (depends on 1)

The method of claim 1, wherein anesthetic agent is procaine or lidocaine.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein said pharmaceutical composition is formulated for oral, transnasal, parenteral, subtopical transepithelial, transdermal patch, subdermal, or inhalation delivery.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein said pharmaceutical composition is formulated as a suspension, capsule, tablet, suppository, lotion, or patch.

### Claim 13

A method of treating or reducing pain comprising administering to a subject in need thereof a therapeutically effective amount of an NMDA receptor antagonist and a second agent, said second agent is an opiate narcotic agent, a non-steroidal anti-inflammatory agent, or an anesthetic.

### Claim 14 (depends on 13)

The method of claim 13, wherein said method does not include administering to said subject a 3-pyridyl ether compound.

### Claim 15 (depends on 13)

The method of claim 13, wherein said pain is caused by a CNS-related condition.

### Claim 16 (depends on 15)

The method of claim 15, wherein said CNS-related condition is Alzheimer's disease or Parkinson's disease.

### Claim 17 (depends on 16)

The method of claim 16, wherein said pain is nociceptive pain.

### Claim 18 (depends on 17)

The method of claim 17, wherein said nociceptive pain is acute pain.

### Claim 19 (depends on 17)

The method of claim 17, wherein the acute pain is post operative pain.

### Claim 20 (depends on 17)

The method of claim 17, wherein the nociceptive pain is chronic pain.

### Claim 21 (depends on 20)

The method of claim 20, wherein the chronic pain is muscoskeletal pain.

### Claim 22 (depends on 13)

The method of claim 13, wherein said combination is administered prophylactically.

### Claim 23 (depends on 13)

The method of claim 13, wherein the combination is administered following the onset of pain in said subject.

### Claim 24 (depends on 13)

The method of claim 13, wherein said NMDA receptor antagonist and said second agent are administered simultaneously or sequentially.

### Claim 25 (depends on 13)

The method of claim 13, wherein said NMDA antagonist and said second agent are administered as a single composition.

### Claim 26 (depends on 13)

The method of claim 13, wherein said NMDA receptor antagonist, second agent, or both is provided in an extended release dosage form.
